Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT ...Middle East

- Patients successfully self-managed PSVT episodes with etripamil which reduced need for ED intervention - - As in other studies, etripamil was well tolerated by patients - - Data to be featured during late breaking session at Heart Rhythm 2022 - MONTREAL and CHARLOTTE, N.C., April 30,...

Hence then, the article about milestone pharmaceuticals announces presentation of data from phase 3 node 302 study of etripamil for the treatment of psvt was published today ( Saturday 30/04/2022 - 04:14 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT )

Also on site :

• Emmys 2026: ‘Widow’s Bay’ Leads All New Shows With 19 Nominations
• Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
• ‘Little House’ Star Alison Arngrim Reveals the Haunting Prediction Michael Landon Made Before He Died